Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 13Active not recruiting 4Terminated 1Suspended 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Breast Neoplasms 33Neoplasms 29Neoplasm Metastasis 23Melanoma 23Leukemia, Myeloid, Acute 20Prostatic Neoplasms 19Colorectal Neoplasms 18Multiple Myeloma 17Lung Neoplasms 16Lymphoma, Non-Hodgkin 14Recurrence 13Myelodysplastic Syndromes 13Squamous Cell Carcinoma of Head and Neck 12Ovarian Neoplasms 12Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Renal Cell 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Glioblastoma 10Carcinoma, Hepatocellular 10Uterine Cervical Neoplasms 9Brain Neoplasms 9Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Rectal Neoplasms 7Lymphoma, Follicular 7Lymphoma 7Hodgkin Disease 7

Interventions

ruxolitinib 1Stem Cell Transplantation 1Liposomes 1Injections 1Daunorubicin 1Cytarabine 1CPX-351 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thrombocythemia, Essential × 90 days × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡